News Releases

June 2021

June 14, 2021 6/14/2021 U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Adult Prophylactic Use of VONVENDI® [von Willebrand factor (Recombinant)]

March 2021

March 1, 2021 3/1/2021 The Children’s National Hospital Rare Disease Institute and Takeda Partner to Standardize Care for Patients With Rare Diseases

December 2020

December 15, 2020 12/15/2020 U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

December 2, 2020 12/2/2020 TAKEDA FURTHER ENABLES HEMOPHILIA A PERSONALIZED CARE WITH LAUNCH OF MYPKFIT® SOFTWARE FOR ADYNOVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED]

November 2020

November 9, 2020 11/9/2020 Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting

October 2020

October 27, 2020 10/27/2020 Takeda to Present Rare Bleeding Disorders Research at Thrombosis & Hemostasis Summit of North America (THSNA) 2020

August 2020

August 10, 2020 8/10/2020 National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

August 1, 2020 8/1/2020 Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020